# Glucocorticoid-Induced alterations in DNA methylation in the H19 promoter of Bone Marrow-Derived Mesenchymal Stem Cells are associated with the pathogenesis of osteonecrosis

**Authors:** Song Gong, Lizhi Han, Yang Wang, Yong Feng, Ruoyu Wang, Shizhan Zhang, Kun Nie, Bo Wang, Fei Du, Jianzhong Guan, Lu Zhang, Jiangtao Liu, Weihua Xu

PMC · DOI: 10.1371/journal.pone.0345372 · PLOS One · 2026-03-27

## TL;DR

This study shows how glucocorticoids cause bone disease by altering DNA methylation in stem cells, offering a new treatment approach.

## Contribution

The novel Dnmt1/H19/GSK-3β regulatory axis in GC-induced ONFH is identified as an epigenetic mechanism and therapeutic target.

## Key findings

- H19 promoter hypomethylation leads to H19 overexpression in undifferentiated GC-ONFH BMSCs.
- Dnmt1 and H19 reciprocally regulate osteogenic and adipogenic differentiation via GSK-3β and Wnt/β-catenin signaling.
- Dnmt1 knockdown or H19 overexpression in BMSCs reduced ONFH progression in a rat model.

## Abstract

Glucocorticoid (GC)-induced osteonecrosis of the femoral head (ONFH) involves bone marrow-derived mesenchymal stem cell (BMSC) apoptosis and dysregulated osteo-adipogenic differentiation. While aberrant H19 promoter methylation and expression have been linked to various bone metabolic disorders such as osteoporosis and osteosarcoma, their specific role in the pathogenesis of GC-induced ONFH remains largely unexplored.

We analyzed H19 promoter methylation, DNMTs, and H19 expression in human ONFH BMSCs. Roles of Dnmt1 and H19 in osteogenic/adipogenic differentiation were assessed using staining (Alizarin Red/Oil Red O) and pathway analysis. Effects of Dnmt1 knockdown or H19 overexpression were tested via BMSC implantation in a GC-induced ONFH rat model.

H19 promoter hypomethylation caused H19 overexpression in undifferentiated GC-ONFH BMSCs; expression decreased upon differentiation. H19 and Dnmt1 expression were negatively correlated. Dnmt1 predominated among DNMTs in epigenetically regulating H19 and reciprocally modulated differentiation (inhibiting osteogenesis, promoting adipogenesis). Conversely, H19 promoted osteogenesis and inhibited adipogenesis by suppressing GSK-3β, activating Wnt/β-catenin signaling. In the rat model, implanted BMSCs with Dnmt1 knockdown or H19 overexpression reduced empty lacunae, corrected the osteo-adipogenic imbalance, and delayed progression.

The Dnmt1/H19/GSK-3β axis reciprocally regulates BMSC osteogenic and adipogenic differentiation in GC-induced ONFH, representing a novel epigenetic mechanism underlying GC-induced ONFH and a promising MSC-based therapeutic strategy for early-stage disease.

## Linked entities

- **Genes:** H19 (H19 imprinted maternally expressed transcript) [NCBI Gene 283120], DNMT1 (DNA methyltransferase 1) [NCBI Gene 1786], GSK3B (glycogen synthase kinase 3 beta) [NCBI Gene 2932]
- **Diseases:** osteoporosis (MONDO:0005298), osteosarcoma (MONDO:0002623)
- **Species:** Homo sapiens (taxon 9606), Rattus norvegicus (taxon 10116)

## Full-text entities

- **Genes:** RIEG2 (Rieger syndrome 2) [NCBI Gene 6012] {aka ARS, RGS2}, RUNX2 (RUNX family transcription factor 2) [NCBI Gene 860] {aka AML3, CBF-alpha-1, CBFA1, CCD, CCD1, CLCD}, GSK3B (glycogen synthase kinase 3 beta) [NCBI Gene 2932], DNMT3B (DNA methyltransferase 3 beta) [NCBI Gene 1789] {aka FSHD4, ICF, ICF1, M.HsaIIIB}, IGF2 (insulin like growth factor 2) [NCBI Gene 3481] {aka C11orf43, GRDF, IGF-II, PP9974, SRS3}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, Dnmt3b (DNA methyltransferase 3 beta) [NCBI Gene 444985], H19 (H19 imprinted maternally expressed transcript) [NCBI Gene 309122] {aka ASM, ASM1, D11S813E}, Dnmt1 (DNA methyltransferase 1) [NCBI Gene 84350], Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 24383] {aka BARS-38, Gapd}, COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277] {aka CAFYD, EDSARTH1, EDSC, OI1, OI2, OI3}, FABP4 (fatty acid binding protein 4) [NCBI Gene 2167] {aka A-FABP, AFABP, ALBP, HEL-S-104, aP2}, DNMT3A (DNA methyltransferase 3 alpha) [NCBI Gene 1788] {aka DNMT3A2, HESJAS, M.HsaIIIA, TBRS}, DNMT1 (DNA methyltransferase 1) [NCBI Gene 1786] {aka ADCADN, AIM, CXXC9, DNMT, HSN1E, MCMT}, Wnt2 (Wnt family member 2) [NCBI Gene 114487] {aka Wnt}, Gsk3b (glycogen synthase kinase 3 beta) [NCBI Gene 84027], Ctrl (chymotrypsin-like) [NCBI Gene 117184], Fabp4 (fatty acid binding protein 4) [NCBI Gene 79451] {aka Albp, aP2}, PPARG (peroxisome proliferator activated receptor gamma) [NCBI Gene 5468] {aka CIMT1, FPLD3, GLM1, NR1C3, PPARG1, PPARG2}, Actb (actin, beta) [NCBI Gene 81822] {aka Actx}, Ctnnb1 (catenin beta 1) [NCBI Gene 84353] {aka Catnb}, Col1a1 (collagen type I alpha 1 chain) [NCBI Gene 29393] {aka COLIA1}, H19 (H19 imprinted maternally expressed transcript) [NCBI Gene 283120] {aka ASM, ASM1, BWS, D11S813E, GMRSP, LINC00008}, Dnmt3a (DNA methyltransferase 3 alpha) [NCBI Gene 444984]
- **Diseases:** calcific aortic valve disease (OMIM:109730), osteosarcoma (MESH:D012516), COVID-19 (MESH:D000086382), fracture (MESH:D050723), inflammatory (MESH:D007249), infectious disease (MESH:D003141), osteoporosis (MESH:D010024), calcific (MESH:D002114), hypertension (MESH:D006973), patella dislocation (MESH:C538081), Alzheimer's disease (MESH:D000544), hip pain and dysfunction (MESH:D013001), weight loss (MESH:D015431), cancer (MESH:D009369), fat (MESH:D004620), cervical dislocation (MESH:D002575), metabolic (MESH:D008659), autoimmune disorders (MESH:D001327), cystic degeneration (MESH:D018297), coagulopathy (MESH:D001778), immunodeficiency (MESH:D007153), diabetes (MESH:D003920), THA (MESH:D025981), degenerative arthritis (MESH:D010003), hematological disorders (MESH:D006402), FNF (MESH:D005265), pain (MESH:D010146), Osteonecrosis of the femoral head (MESH:D000070603), bone metabolism disorders (MESH:D001851), osteonecrosis (MESH:D010020), heart disease (MESH:D006331), bone diseases (MESH:D001847), death (MESH:D003643), tumorigenesis (MESH:D063646), GC (MESH:C564221), aortic valve disease (MESH:D000082862), infection (MESH:D007239)
- **Chemicals:** Alizarin Red (MESH:C010078), water (MESH:D014867), isopropanol (MESH:D019840), polyacrylamide (MESH:C016679), Alizarin Red S (MESH:C004468), buprenorphine (MESH:D002047), 5-bromo-2-deoxyuridine (MESH:D001973), steroid (MESH:D013256), LPS (MESH:D008070), ATP (MESH:D000255), uracil (MESH:D014498), CO2 (MESH:D002245), Hematoxylin (MESH:D006416), L-ascorbic acid (MESH:D001205), DMSO (MESH:D004121), penicillin (MESH:D010406), Bisulfite (MESH:C042345), H&amp;E (MESH:D006371), IBMX (MESH:D015056), PBS (MESH:D007854), Blood Glucose (MESH:D001786), rosiglitazone (MESH:D000077154), Tideglusib (MESH:C520571), ORO (MESH:C011049), paraffin (MESH:D010232), 5-aza-2'-deoxycytidine (MESH:D000077209), EDTA (MESH:D004492), TRIzol (MESH:C411644), dexamethasone (MESH:D003907), lipid (MESH:D008055), Fat (MESH:D005223), prednisolone (MESH:D011239), Eosin (MESH:D004801), DAPI (MESH:C007293), alcohol (MESH:D000438), SDS (MESH:D012967), PFA (MESH:C003043), cytosine (MESH:D003596), CCK-8 (MESH:D012844), sodium pentobarbital (MESH:D010424), beta-glycerophosphate (MESH:C031463), Triton X-100 (MESH:D017830), MPS (MESH:D008775), Lipofectamine 2000 (MESH:C086724), L-glutamine (MESH:D005973), streptomycin (MESH:D013307), PVDF (MESH:C024865), cetylpyridinium chloride (MESH:D002594), calcium (MESH:D002118), DMEM-F12 (-), polybrene (MESH:D006583)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13028513/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13028513/full.md

## References

72 references — full list in the complete paper: https://tomesphere.com/paper/PMC13028513/full.md

---
Source: https://tomesphere.com/paper/PMC13028513